Matthew Purbaugh, MD
Neurology · Lincoln, NENPI 1437640067
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,950 of the $6,720 with a category attached, or 73.7%. Amgen accounts for 88.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $6,241 and has fallen 95.1% since, to $305 in 2025.
Across 42 payments — averaging $159.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- AbbVie$275
- Medtronic$102
- UCB, Inc.$95
- Novartis$52
- Pfizer$34
- plus $203 from 11 others
What the payments were for
- Speaking & faculty fees$4,95074%
- Travel & lodging$73711%
- Food & beverage$1,03315%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 10 | $5,958 |
| AbbVie | 11 | $275 |
| Medtronic | 1 | $102 |
| UCB, Inc. | 4 | $95 |
| Novartis | 3 | $52 |
| Pfizer | 2 | $34 |
| EMD Serono, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| GE HealthCare | 1 | $19 |
| Tonix Medicines, Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Biogen | 1 | $18 |
| Banner Life Sciences, LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| CSL Behring | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,720 in reported general payments places this provider in the 75th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 89 | $2,295 |
| Lacosamide | 15 | $1,191 |
| Clobazam | 13 | $466 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $379 |
| Divalproex Sodium | 12 | $336 |
| Donepezil Hcl | 21 | $336 |
| Atorvastatin Calcium | 15 | $53 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lincoln
- Gary PatteeLincoln$132K
- James BobenhouseLincoln$14K
- Ana DelgadoLincoln$11K
- Brian BoesLincoln$8K
- Michael VavraLincoln$7K
- Matthew KnissLincoln$5K
- Daniel Crespo ArtunduagaLincoln$5K
- Vekash RajaLincoln$3K
- Erin DennisLincoln$2K
- Navya JosephLincoln$768
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.